Donor transmission of malignant melanoma in a lung transplant recipient 32 years after curative resection

Transplant International

Volumn 23, Issue 7, 2010, Pages

  Bajaj, Navkaranbir S ^a   Watt, Christopher ^b   Hadjiliadis, Denis ^b   Gillespie, Colin ^b   Haas, Andrew R ^b   Pochettino, Alberto ^b   Mendez, James ^b   Sterman, Daniel H ^b   Schuchter, Lynn M ^b   Christie, Jason D ^b   Lee, James C ^b   Ahya, Vivek N ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Donor selection criteria; Long term complications; Lung transplantation (clinical); Malignancies; Organ donation

Indexed keywords

AZATHIOPRINE; DACLIZUMAB; PREDNISONE; RAPAMYCIN; TACROLIMUS; TEMOZOLOMIDE;

ADULT; ARTICLE; BRACHYTHERAPY; BRONCHOSCOPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE TRANSMISSION; DNA FINGERPRINTING; GRAFT RECIPIENT; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TRANSPLANTATION; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; ORGAN DONOR; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; SHORT TANDEM REPEAT; SPIROMETRY; TUMOR BIOPSY; DONOR; DONOR SELECTION; FATALITY; FEMALE; LUNG NEOPLASMS; MIDDLE AGED; PULMONARY FIBROSIS; SKIN TUMOR;

DONOR SELECTION; FATAL OUTCOME; FEMALE; HUMANS; LUNG NEOPLASMS; LUNG TRANSPLANTATION; MALE; MELANOMA; MIDDLE AGED; PULMONARY FIBROSIS; SKIN NEOPLASMS; TISSUE DONORS;

EID: 77953222311     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01090.x     Document Type: Article

References (40)

1. American Cancer Society. Cancer Facts & Figures 2008. Atlanta: American Cancer Society, 2008. Available at: http://www.cancer.org/downloads/ STT/2008CAFFfinalsecured.pdf (accessed on 22 April 2010).
2. Van Raemdonck D, Neyrinck A, Verleden GM, et al. Lung donor selection and management. Proc Am Thorac Soc 2009 6 : 28.
3. de Perrot M, Snell GI, Babcock WD, et al. Strategies to optimize the use of currently available lung donors. J Heart Lung Transplant 2004 23 : 1127.
4. Butler JM. Short tandem repeat typing technologies used in human identity testing. BioTechniques 2007 43 : ii.
5. Leonard DGB, ed. Molecular Pathology in Clinical Practice. New York: Springer, 2007.
6. Van Deerlin VM, Leonard DG. Bone Marrow Engraftment Analysis after Allogeneic Bone Marrow Transplantation. Clin Lab Med 2000 20 : 197.
7. Meier F, Guenova E, Clasen S, et al. Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients. J Am Acad Dermatol 2009 60 : 863.
8. Kauffman HM, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation 2000 70 : 1747.
9. Buell JF, Beebe TM, Trofe J, et al. Donor transmitted malignancies. Ann Transplant 2004 9 : 53.
10. Ison MG, Hager J, Blumberg E, et al. Donor-derived disease transmission events in the united states: data reviewed by the OPTN/UNOS disease transmission advisory committee. Am J Transplant 2009 9 : 1929.
11. Boi S, Amichetti M. Late metastases of cutaneous melanoma: case report and literature review. J Am Acad Dermatol 1991 24 : 335.
12. Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 1997 79 : 2361.
13. Crowley NJ, Seigler HF. Late recurrence of malignant melanoma. Analysis of 168 patients. Ann Surg 1990 212 : 173.
14. Boutis A, Valeri R, Korantzis I, Valoukas D, Andronikidis I, Andreadis C. Delayed malignant melanoma recurrence simulating primary ovarian cancer: case report. World J Surg Oncol 2008 6 : 124.
15. Schmid-Wendtner MH, Baumert J, Schmidt M, et al. Late metastases of cutaneous melanoma: an analysis of 31 patients. J Am Acad Dermatol 2000 43 : 605.
16. Levy E, Silverman MK, Vossaert KA, et al. Late recurrence of malignant melanoma: a report of five cases, a review of the literature and a study of associated factors. Melanoma Res 1991 1 : 63.
17. Raderman D, Giler S, Rothem A, Ben-Bassat M. Late metastases (beyond ten years) of cutaneous malignant melanoma. Literature review and case report. J Am Acad Dermatol 1986 15 : 374.
18. Tahery DP, Moy RL. Lack of predictive factors in late recurrence of stage I melanoma. Int J Dermatol 1992 31 : 629.
19. Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 2009 19 : 275.
20. Polak ME, Borthwick NJ, Jager MJ, Cree IA. Melanoma vaccines: the problems of local immunosuppression. Hum Immunol 2009 70 : 331.
21. Lengagne R, Graff-Dubois S, Garcette M, et al. Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases. J Immunol 2008 180 : 130.
22. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996 61 : 274.
23. Kim JK, Carmody IC, Cohen AJ, Loss GE. Donor transmission of malignant melanoma to a liver graft recipient: case report and literature review. Clin Transplant 2009 23 : 571.
24. Cankovic M, Linden MD, Zarbo RJ. Use of microsatellite analysis in detection of tumor lineage as a cause of death in a liver transplant patient. Arch Pathol Lab Med 2006 130 : 529.
25. Suranyi MG, Hogan PG, Falk MC, et al. Advanced donor-origin melanoma in a renal transplant recipient: immunotherapy, cure, and retransplantation. Transplantation 1998 66 : 655.
26. Milton CA, Barbara J, Cooper J, Rao M, Russell C, Russ G. The transmission of donor-derived malignant melanoma to a renal allograft recipient. Clin Transplant 2006 20 : 547.
27. MacKie RM, Reid R, Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Eng J Med 2003 348 : 567.
28. Elder GJ, Hersey P, Branley P. Remission of transplanted melanoma - clinical course and tumour cell characterisation. Clin Transplant 1997 11 : 565.
29. Warshawsky I, Farver C, Paul P, Mehta A, Decamp MM. Importance of metastatic site analysis in determining tumor lineage in a lung transplant recipient. Transplantation 2005 79 : 858.
30. Stephens JK, Everson GT, Elliott CL, et al. Fatal transfer of malignant melanoma from multiorgan donor to four allograft recipients. Transplantation 2000 70 : 232.
31. Morris-Stiff G, Steel A, Savage P, et al. Transmission of donor melanoma to multiple organ transplant recipients. Am J Transplant 2004 4 : 444.
32. Domhan S, Zeier M, Abdollahi A. Immunosuppressive therapy and post-transplant malignancy. Nephrol Dial Transplant 2009 24 : 1097.
33. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Eng J Med 2003 348 : 1681.
34. Loren AW, Tsai DE. Post-transplant lymphoproliferative disorder. Clin Chest Med 2005 26 : 631, vii.
35. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006 17 : 581.
36. Buell JF, Trofe J, Hanaway MJ, et al. Transmission of donor cancer into cardiothoracic transplant recipients. Surgery 2001 130 : 660, discussion 6
37. Veness MJ, Quinn DI, Ong CS, et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer 1999 85 : 1758.
38. Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW. Deceased donors with a past history of malignancy: an organ procurement and transplantation network/united network for organ sharing update. Transplantation 2007 84 : 272.
39. Cotter MA, Tristani-Firouzi P. Unsuitability of organ donation from a patient with a history of melanoma? J Am Acad Dermatol 2006 54 : 1096.
40. Collignon FP, Holland EC, Feng S. Organ donors with malignant gliomas: an update. Am J Transplant 2004 4 : 15.